HR Execs on the Move

Graybug Vision

www.graybug.vision

 
Every day, Graybug Vision works relentlessly to make healthy vision more accessible and more manageable for patients with chronic vision-threatening eye diseases. We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. Our novel technologies are designed to release drugs in ocular tissue at a controlled rate for up to 12 months in order to improve patient compliance, reduce healthcare burdens and, ultimately, deliver better clinical outcomes.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.graybug.vision
  • 275 Shoreline Drive Suite 450
    Redwood City, CA USA 94065
  • Phone: 650.487.2800

Executives

Name Title Contact Details
Bettina Maunz
Chief People Officer Profile

Similar Companies

Evergreen Theragnostics

Evergreen Theragnostics was established in 2019 to be a leading US-based radiopharmaceutical Contract Development and Manufacturing Organization (CDMO).

BASS Medical Group

Headquartered in Walnut Creek, CA, BASS Medical Group is the Greater Bay Area’s leading healthcare specialist provider. With over 300 providers, 200 locations, & 42 specialties, BASS provides state-of-the-art care in a family setting. Known for its sma...

OPEN Health

We provide deep scientific knowledge, global understanding and broad expertise to enhance market access and medical communications for improved health outcomes.

Cerevel

Cerevel Therapeutics is a biopharmaceutical company focused on developing new therapies to treat disorders of the central nervous system (CNS). The company has a portfolio of experimental neuroscience therapies, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders, including Parkinson`s, Alzheimer`s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.